Image-guided robotic stereotactic body radiation therapy for liver XXXX : is there a dose response relationship?

@entity1 @entity137 @entity390 @entity14 @entity3
PURPOSE: To evaluate the outcome, tolerance, and @entity137 of stereotactic body radiotherapy, using image-guided robotic radiation delivery, for the treatment of @entity1 with unresectable liver @entity3 . METHODS AND MATERIAL: @entity1 were treated with real-time respiratory tracking between July 2007 and April 2009. Their records were retrospectively reviewed. Metastases from @entity14 and other primaries were not necessarily confined to liver. @entity137 was evaluated using National Cancer Institute Common Criteria for Adverse Events version 3.0. RESULTS: Forty-two @entity1 with 62 @entity3 were treated with two dose levels of 40 Gy in four Dose per Fraction (23) and 45 Gy in three Dose per Fraction (13). Median follow-up was 14.3 months (range, 3-23 months). Actuarial local control for 1 and 2 years was 90% and 86%, respectively. At last follow-up, 41 (66%) complete responses and eight (13%) partial responses were observed. Five lesions were stable. Nine lesions (13%) were locally progressed. Overall survival was 94% at 1 year and 48% at 2 years. The most common @entity137 was Grade 1 or 2 @entity390 . One @entity1 experienced Grade 3 epidermitis. The dose level did not significantly contribute to the outcome, @entity137 , or survival. CONCLUSION: Image-guided robotic stereotactic body radiation therapy is feasible, safe, and effective, with encouraging local control. It provides a strong alternative for @entity1 who cannot undergo surgery.
